-
10-Year UK Study Says Disease Modifying Therapies for MS Slow Disease Progression, Save Costs
Four disease-modifying therapies (DMTs) for multiple sclerosis — Avonex, Rebif, Betaferon, and Copaxone — are cost-effective and reduce disease progression in MS patients, especially those with relapsing-remitting disease, according to 10-year, real-world results from U.K.’s MS Risk Sharing Scheme (RSS).
Are any of these DMTs part of your treatment plan? What do you think of this long-term study’s findings?
-
1 Reply
-
Is it just a coincidence that these are the older DMTs, e.g. Avonex and Copaxone? This study could be used by NICE, in the UK, to justify its position that Ocrevus shouldn’t be available in the National Health Service because they don’t consider it to be cost-effective.
Ed
Log in to reply.